Celanese Corporation
CE
$65.09
+0.68%
Celanese Corporation is a global chemical technology company and a leading producer of acetic acid and its downstream derivatives, as well as specialty polymers used in coatings, adhesives, automotive, electronics, and medical end markets. The company holds a distinct position as a major integrated producer in the acetyl chain and a key supplier of high-performance engineered materials. The current investor narrative revolves around navigating a volatile chemical cycle, marked by a significant recovery in its stock price from multi-year lows, as the market debates the sustainability of its margin recovery and cash flow generation amidst mixed quarterly results, including a recent return to profitability in Q4 2025 after a substantial loss in the prior quarter.…
CE
Celanese Corporation
$65.09
Investment Opinion: Should I buy CE Today?
Rating: Hold. The core thesis is that CE is a high-risk, high-potential-reward cyclical recovery story currently priced near fair value after a massive rally, warranting a cautious stance until earnings stability is demonstrated.
Supporting evidence includes a forward P/E of 10.08 based on analyst EPS forecasts of $11.95, which is reasonable but not deeply discounted for a cyclical stock. The trailing PS ratio of 0.49 is at a historical low, suggesting embedded recovery potential, but this is counterbalanced by a negative trailing ROE of -28.77% and a quarterly revenue decline of -7.0% YoY. Positive catalysts include robust TTM free cash flow of $803 million and a recent upgrade by Wells Fargo to 'Overweight', signaling some institutional belief in the turnaround.
The thesis would upgrade to a Buy if the company reports consecutive quarters of positive and growing net income, confirming the cyclical recovery, and if the stock pulls back to the $50-$55 support zone, offering a better margin of safety. It would downgrade to a Sell if Q4 profitability proves fleeting and the company returns to significant losses, or if revenue decline accelerates beyond -10% YoY. Based on the current data, the stock appears fairly valued relative to its recovery prospects but overvalued relative to its still-volatile fundamentals.
Sign up to view all
CE 12-Month Price Forecast
The outlook for CE is bifurcated between its powerful technical momentum and its still-fragile fundamentals. The market is pricing in a significant earnings recovery (forward P/E 10.08), but this is predicated on reversing a trend of revenue declines and extreme profit volatility. The strong free cash flow is a key positive, but high leverage amplifies all risks. The neutral stance reflects the view that the stock has run ahead of its confirmed fundamental improvement. The stance would upgrade to bullish on evidence of sustained quarterly profit growth and revenue stabilization. It would turn bearish if the next earnings report shows a return to losses or a further acceleration in top-line decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celanese Corporation's 12-month outlook, with a consensus price target around $84.62 and implied upside of +30.0% versus the current price.
Average Target
$84.62
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$52 - $85
Analyst target range
Analyst coverage for Celanese is limited, with only 5 analysts providing estimates, indicating it is a mid-cap stock with moderate institutional interest. The consensus recommendation cannot be precisely determined from the given data, but recent institutional ratings show a mix of 'Buy'/'Overperform' (Citigroup, Baird, Wells Fargo upgrade), 'Neutral'/'Sector Perform' (UBS, JP Morgan, RBC), and 'In Line' (Evercore), suggesting a cautiously optimistic to neutral sentiment overall. The average target price is not explicitly provided in the analyst data, which only gives EPS and revenue estimates. Therefore, the implied upside/downside to a consensus target cannot be calculated. The target price range is also not available in the provided dataset. The recent pattern of ratings includes an upgrade by Wells Fargo to 'Overweight' from 'Equal Weight' on March 13, 2026, which is a positive signal, while other firms have largely maintained neutral stances. The limited number of analysts and the absence of a clear target price range in the data suggest higher uncertainty and potentially less efficient price discovery, which can contribute to the stock's observed volatility. Investors should seek out the specific consensus price target from other sources to gauge the near-term expected return.
Bulls vs Bears: CE Investment Factors
The bull case, centered on a powerful cyclical recovery supported by deep valuation discount and strong cash flow, currently holds stronger evidence given the stock's explosive 48.7% annual gain and the market's forward-looking EPS expectations. However, the bear case, grounded in extreme fundamental volatility, high leverage, and persistent revenue declines, presents a formidable counter-argument. The single most important tension in the investment debate is whether the recent return to profitability in Q4 marks a sustainable inflection point in the chemical cycle or merely a temporary respite before further earnings volatility. The resolution of this tension—specifically, the stabilization of revenue and a consistent return to positive, growing net income—will determine if the current low valuation is a trap or a tremendous opportunity.
Bullish
- Powerful Technical Uptrend: The stock has surged +48.71% over the past year and +53.99% over the last six months, decisively breaking out from its 52-week low of $35.13. This momentum, with the price at 95% of its 52-week high, signals strong market conviction in a cyclical recovery.
- Attractive Valuation on Sales: Trading at a trailing Price-to-Sales ratio of 0.49, CE is near the bottom of its historical valuation range, where PS ratios were above 2.0 in 2023-2024. This deep discount prices in significant cyclical distress, offering substantial upside if earnings normalize.
- Despite earnings volatility, the company generated $803 million in trailing twelve-month free cash flow. This robust cash generation provides a critical buffer to service its high debt load and supports potential shareholder returns or reinvestment.
- Analyst Forecasts Sharp EPS Recovery: Analysts project forward EPS of $11.95, implying a forward P/E of just 10.08. This stark contrast to the negative trailing P/E (-3.97) indicates the market expects a dramatic earnings rebound from the Q3 2025 net loss of -$1.357 billion.
Bearish
- Extreme Earnings Volatility & Negative ROE: Profitability is wildly inconsistent, swinging from a $199 million net income in Q2 2025 to a -$1.357 billion loss in Q3. This volatility results in a deeply negative Return on Equity of -28.77%, indicating poor returns on a highly leveraged capital structure.
- High Financial Leverage: The company's debt-to-equity ratio stands at 3.19, indicating a highly leveraged balance sheet. This amplifies financial risk, making the company vulnerable to interest rate shifts and compressing margins during downturns, as seen with $214M in Q4 interest expense.
- Persistent Revenue Decline: Q4 2025 revenue of $2.204 billion represents a -7.0% year-over-year decline, continuing a multi-quarter downtrend from $2.652 billion in Q3 2024. This top-line pressure, driven by demand softness and pricing, challenges the sustainability of any recovery.
- Compressed & Volatile Margins: The Q4 2025 gross margin of 17.38% is significantly below the reported valuation gross margin of 22.74%, indicating severe quarterly pressure. Operating income has swung from $233M to -$1.275B in recent quarters, highlighting fundamental instability.
CE Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +48.71% and a 6-month gain of +53.99%. As of the latest close at $65.00, the price is trading at approximately 95% of its 52-week high of $68.77, indicating it is near the peak of its recent range and testing a critical resistance level. This positioning suggests strong momentum but also raises the risk of overextension and potential consolidation if the resistance holds. Recent momentum remains robust but shows signs of volatility; the stock gained +36.78% over the last 3 months, significantly outpacing the S&P 500's +3.59%, yet the 1-month gain of +3.73% has decelerated relative to the longer-term trend and underperformed the market's +8.7% surge, hinting at a potential short-term pause or rotation. The Relative Strength Index (RSI) data is not provided, but the price action from the data shows sharp rallies followed by pullbacks, such as the surge to over $68 in mid-April and a subsequent drop to $62.03, indicating volatile, momentum-driven trading. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $68.77 and support at the 52-week low of $35.13. A decisive breakout above $68.77 would signal a continuation of the bullish trend, while a failure could lead to a retest of the $50-$55 consolidation zone. With a beta of 0.848, the stock has historically been about 15% less volatile than the broader market, but its recent price swings suggest this low-beta characteristic may be breaking down, requiring careful risk management despite the overall lower systemic risk profile.
Beta
0.85
0.85x market volatility
Max Drawdown
-43.0%
Largest decline past year
52-Week Range
$35-$69
Price range past year
Annual Return
+46.3%
Cumulative gain past year
| Period | CE Return | S&P 500 |
|---|---|---|
| 1m | +1.3% | +12.6% |
| 3m | +43.2% | +2.5% |
| 6m | +69.3% | +4.3% |
| 1y | +46.3% | +28.4% |
| ytd | +54.4% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CE Fundamental Analysis
Revenue trajectory remains challenging but shows signs of stabilization; the most recent quarterly revenue for Q4 2025 was $2.204 billion, representing a year-over-year decline of -7.0%. The multi-quarter trend is volatile, with revenue declining from $2.652 billion in Q3 2024 to a low of $2.204 billion in Q4 2025, indicating persistent top-line pressure, likely from demand softness and pricing. Segment data shows the Engineered Materials segment generated $1.277 billion, larger than the Acetyl Chain's $0.940 billion in the latest period, suggesting the former is the primary revenue driver, though both segments face headwinds given the overall decline. Profitability is highly inconsistent, swinging from a massive net loss of -$1.357 billion in Q3 2025 to a net income of $19 million in Q4 2025. The gross margin for Q4 2025 was 17.38%, which is compressed compared to the 22.74% gross margin from the valuation data, indicating significant quarterly pressure on input costs or pricing. The operating margin of 8.04% from the valuation data suggests the company can generate operating profit, but bottom-line results are heavily impacted by non-operating items like interest expense and impairments, as seen in the disastrous Q3. The balance sheet carries significant financial leverage, with a debt-to-equity ratio of 3.19, indicating a highly leveraged capital structure that amplifies risk. However, liquidity appears adequate with a current ratio of 1.55, and the company generated substantial trailing twelve-month free cash flow of $803 million, providing a crucial buffer to service its debt. The negative Return on Equity (ROE) of -28.77% reflects the impact of recent large losses on shareholder equity, highlighting the challenge of generating acceptable returns under the current capital structure and earnings volatility.
Quarterly Revenue
$2.2B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.17%
Latest Quarter
Free Cash Flow
$803000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CE Overvalued?
Given the trailing twelve-month net income is negative (EPS of -$0.25), the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.49 and an Enterprise Value-to-Sales (EV/Sales) of 2.02. The forward PE ratio of 10.08 is also meaningful as it implies the market expects a return to profitability, with analysts forecasting EPS of $11.95 for the coming period. The significant gap between the negative trailing PE and the positive forward PE of 10.08 underscores the market's expectation of a sharp earnings recovery from the depressed base. Compared to industry averages, specific sector multiples are not provided in the data, but a PS ratio of 0.49 appears low for a chemical company, potentially indicating a discount if normalized earnings power is higher. The EV/EBITDA multiple of 55.82 is exceptionally high, but this is distorted by temporarily depressed EBITDA; a more normalized earnings base would bring this ratio down substantially. Historically, the stock's own valuation has compressed dramatically; the current PS ratio of 0.49 is near the bottom of its historical range, as seen in the historical ratios data where PS ratios were above 2.0 for much of 2023-2024 and even above 5.0 in 2021-2022. Trading near historical valuation lows suggests the market is pricing in significant fundamental deterioration or cyclical trough conditions, presenting a potential value opportunity if the company's earnings recovery materializes as forecasted.
PE
-4.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -74x~61x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, primarily stemming from extreme earnings volatility and high financial leverage. The company's net income swung from +$199 million to -$1.357 billion between Q2 and Q3 of 2025, demonstrating fundamental instability that makes forecasting difficult. A debt-to-equity ratio of 3.19 means the capital structure is highly leveraged, amplifying losses and creating vulnerability to rising interest rates, as evidenced by $214 million in interest expense last quarter. Furthermore, revenue has declined sequentially for multiple quarters, with a -7.0% YoY drop in Q4, indicating persistent demand or pricing headwinds that could delay a full recovery.
Market & Competitive Risks include valuation compression and cyclical sensitivity. While the PS ratio of 0.49 appears cheap, the forward P/E of 10.08 is not excessively low for a cyclical chemical stock, leaving limited room for multiple expansion if growth disappoints. The stock's beta of 0.848 suggests it is historically less volatile than the market, but its recent 53.99% six-month surge and sharp pullbacks indicate this characteristic may be breaking down, introducing higher volatility risk. As a basic materials company, CE is highly sensitive to global industrial demand and input cost inflation, making its fortunes heavily dependent on a broad macroeconomic recovery that remains uncertain.
Worst-Case Scenario involves a reversion to the deep losses seen in Q3 2025, triggered by a renewed downturn in chemical demand or a spike in input costs that crushes already compressed margins. In this adverse scenario, the high debt load would become a severe burden, potentially leading to credit rating downgrades and a collapse in investor confidence. The stock could realistically retrace a significant portion of its rally, falling back towards its 52-week low of $35.13. From the current price of $65.00, this represents a potential downside of approximately -46%, aligning with the stock's historical maximum drawdown of -43.05%.
FAQ
The key risks, in order of severity, are: 1) Fundamental Volatility: Extreme swings in profitability, as seen in the jump from a -$1.357B loss to a $19M profit between consecutive quarters, make the stock unpredictable. 2) High Financial Leverage: A debt-to-equity ratio of 3.19 amplifies losses and creates vulnerability to rising rates. 3) Cyclical Demand Risk: As a chemical producer, CE's revenue (-7.0% YoY) is directly tied to global industrial health, which remains uncertain. 4) Technical Overextension: After a 48.7% annual surge, the stock is testing major resistance at $68.77, raising the risk of a sharp pullback.
The 12-month forecast is highly scenario-dependent. The base case (50% probability) sees the stock trading between $60 and $70 as the company stabilizes earnings near analyst EPS forecasts of $11.95. The bull case (30% probability) projects a breakout to $75-$85 on a stronger-than-expected cyclical recovery and margin expansion. The bear case (20% probability) warns of a drop to $35-$50 if profitability evaporates and the high debt load becomes a crisis. The base case is most likely, predicated on the assumption that CE can maintain quarterly profitability, albeit with continued volatility, but fails to deliver robust growth that would justify a higher valuation multiple.
CE sends mixed valuation signals. It appears deeply undervalued on a trailing sales basis, with a PS ratio of 0.49 near multi-year lows, suggesting the market is pricing in severe distress. Conversely, its forward P/E of 10.08 is reasonable but not cheap for a cyclical company, implying the market already expects a significant earnings recovery. Compared to its own history where PS ratios were above 2.0, the stock looks undervalued. However, relative to its current volatile fundamentals—negative ROE and declining revenue—the valuation seems fair, if not fully reflective of the ongoing risks. The market is paying a fair price for a hoped-for, but not yet proven, recovery.
CE is a speculative buy for investors comfortable with high volatility and cyclical risk. The potential reward is anchored by a historically low Price-to-Sales ratio of 0.49 and analyst expectations for a sharp earnings rebound (forward P/E 10.08). However, it is not a 'good buy' for all investors, given its extreme earnings swings, high debt (D/E of 3.19), and persistent revenue declines. It may be suitable for tactical investors seeking exposure to a chemical sector recovery, but they must be prepared for significant downside risk, potentially as high as -46% to the 52-week low, if the recovery falters.
CE is not suitable for short-term trading due to its high fundamental volatility and the unpredictable nature of chemical cycles, which can lead to sharp price swings as recently observed. Its low dividend yield of 0.28% does not support an income strategy. The stock is best approached as a medium-to-long-term (2-3 year) tactical holding for investors betting on a full cyclical recovery. This horizon allows time for the company to demonstrate sustained profitability, reduce leverage, and for the valuation discount to potentially close. A minimum holding period through at least two more quarterly earnings reports is advised to assess the durability of the turnaround.